Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this webinar, Dr Craig Chepke will review considerations in the use of DTx including nuances in the regulatory pathway, clinical trial design, interpretation of the data, and some current evidence for DTx in the management of MDD.
In this webinar, Dr Craig Chepke will review considerations in the use of DTx including nuances in the regulatory pathway, clinical trial design, interpretation of the data, and some current evidence for DTx in the management of MDD.
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video, Craig Chepke, MD, DFAPA, discusses real-world findings that clinicians should be aware of when considering the use of oral or LAI antipsychotics for schizophrenia treatment.
In this video, Craig Chepke, MD, DFAPA, discusses real-world findings that clinicians should be aware of when considering the use of oral or LAI antipsychotics for schizophrenia treatment.
Andrew J. Cutler, MD; Rakesh Jain, MD, MPH, RD; Desiree Matthews, PHMNP-BC; Greg Mattingly, MD
This discussion focuses on how clinicians can apply a wider view of attention-deficit/hyperactivity disorder (ADHD) to address residual symptoms of emotional dysregulation and executive dysfunction.
This discussion focuses on how clinicians can apply a wider view of attention-deficit/hyperactivity disorder (ADHD) to address residual symptoms of emotional dysregulation and executive dysfunction.
Andrew J. Cutler, MD; Rakesh Jain, MD, MPH, RD; Desiree Matthews, PHMNP-BC; Greg Mattingly, MD
Leading psychiatrists explore the evolving neurobiological basis of attention-deficit/hyperactivity disorder (ADHD) symptoms and how it can inform integrative approaches to treatment.
Leading psychiatrists explore the evolving neurobiological basis of attention-deficit/hyperactivity disorder (ADHD) symptoms and how it can inform integrative approaches to treatment.
Andrew J. Cutler, MD; Rakesh Jain, MD, MPH, RD; Desiree Matthews, PHMNP-BC; Greg Mattingly, MD
In this chapter, experts examine the broader clinical presentation of attention-deficit/hyperactivity disorder (ADHD) and the need for comprehensive assessments to inform treatment planning.
In this chapter, experts examine the broader clinical presentation of attention-deficit/hyperactivity disorder (ADHD) and the need for comprehensive assessments to inform treatment planning.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
